Testing effectiveness (Phase 2)Ended earlyNCT03298412
What this trial is testing
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Who this might be right for
High-risk Diffuse Large B-cell Lymphoma
Amgen 10